In the race against the COVID-19 pandemic, the global scientific community has been working tirelessly to develop a safe & effective vaccine. One of the most promising candidates in India is Zydus Cadila’s needle-free COVID-19 vaccine, Zycov-D. In this article, we will explore the details of this vaccine, its benefits, & its potential to fight the ongoing pandemic.
The Zydus Cadila’s vaccine, Zycov-D, is a DNA-based vaccine that has been developed using a plasmid DNA platform. The vaccine has been designed to elicit an immune response against the spike protein of the SARS-CoV-2 virus, which causes COVID-19!
Development and Approval
Zycov-D was developed by Zydus Cadila, an Indian pharmaceutical company that has a track record of developing & manufacturing affordable vaccines for various diseases. The vaccine has undergone extensive preclinical & clinical trials, & the results have been promising.
The vaccine has received approval from the Drug Controller General of India (DCGI) for emergency use in India in August 2021. This makes Zycov-D the world’s first needle-free COVID-19 vaccine.
How Does Zycov-D Work?
Zycov-D works by delivering the genetic material of the spike protein of the SARS-CoV-2 virus into the body’s cells. The vaccine uses a small, circular piece of DNA called a plasmid that contains the genetic instructions to make the spike protein!
Once the DNA enters the body’s cells, it instructs the cells to produce the spike protein. The immune system then recognizes the spike protein as foreign & generates an immune response against it. This immune response prepares the body to fight the virus if it encounters it in the future.
Benefits of Zycov-D
One of the biggest advantages of Zycov-D is that it is a needle-free vaccine. This means that it does not require a needle to administer the vaccine. Instead, it uses a small device called a “needle-free injection system” to deliver the vaccine into the skin!
The needle-free system is painless & can be administered by healthcare workers with minimal training. This makes the vaccine more accessible, especially in remote areas where healthcare facilities may be limited.
Another advantage of Zycov-D is that it does not require any cold storage. This is because the vaccine is stable at room temperature for up to three months, making it easier to transport and store.
Clinical Trials and Efficacy
Zycov-D has undergone extensive clinical trials, & the results have been promising. In phase 1 & 2 clinical trials, the vaccine was found to be safe & well-tolerated. The vaccine also generated a strong immune response against the virus.
In a phase 3 clinical trial, Zycov-D was found to have an efficacy rate of 66.6% against symptomatic COVID-19 cases. The vaccine also showed an efficacy rate of 100% against moderate & severe COVID-19 cases. These results make Zycov-D a promising candidate in the fight against the ongoing pandemic.
Availability and Distribution
Zydus Cadila has announced that it plans to manufacture 10-12 crore doses of Zycov-D annually. The vaccine is expected to be available for use in India by October 2021.
The vaccine will be distributed through the government’s vaccination program & private healthcare providers. The Indian government has also announced that the vaccine will be available for free to all eligible citizens.
You can read this similar topics article:
rajkotupdates.news : zydus needle free corona vaccine zycov d
Zycov-D is a promising candidate in the fight against the COVID-19 pandemic. Its needle-free & room-temperature stability make it a more accessible & convenient option for vaccine administration, especially in remote areas. The vaccine has undergone extensive clinical trials & has shown promising results in generating a strong immune response against the virus. With its approval for emergency use in India, Zycov-D has the potential to help control the spread of COVID-19 in the country!